Cargando…

Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II Studies

OBJECTIVE: To use cell‐based gene signatures to identify patients with systemic lupus erythematous (SLE) in the phase II/III APRIL–SLE and phase IIb ADDRESS II trials most likely to respond to atacicept. METHODS: A published immune cell deconvolution algorithm based on Affymetrix gene array data was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Studham, Matthew, Vazquez‐Mateo, Cristina, Samy, Eileen, Haselmayer, Philipp, Aydemir, Aida, Rolfe, P. Alexander, Merrill, Joan T., Morand, Eric F., DeMartino, Julie, Kao, Amy, Townsend, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570667/ https://www.ncbi.nlm.nih.gov/pubmed/37710418 http://dx.doi.org/10.1002/acr2.11594

Ejemplares similares

Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders
por: Isenberg, David A., et al.
Publicado: (2020)

Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study
por: Morand, Eric F, et al.
Publicado: (2020)

Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials
por: Pitsiu, Maria, et al.
Publicado: (2023)

Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria
por: Barratt, Jonathan, et al.
Publicado: (2022)

Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme
por: Gordon, Caroline, et al.
Publicado: (2019)

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus
por: Cogollo, Estafania, et al.
Publicado: (2015)

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus [Corrigendum]
Publicado: (2015)

Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty‐Four–Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Arm, Phase IIb Study
por: Merrill, Joan T., et al.
Publicado: (2018)

No interactions between heparin and atacicept, an antagonist of B cell survival cytokines
por: Kowalczyk‐Quintas, Christine, et al.
Publicado: (2019)

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial
por: Ginzler, Ellen M, et al.
Publicado: (2012)

Site-specific N- and O-glycosylation analysis of atacicept
por: Stavenhagen, Kathrin, et al.
Publicado: (2019)

Kinetics of free and ligand-bound atacicept in human serum
por: Eslami, Mahya, et al.
Publicado: (2022)

Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
por: Isenberg, David, et al.
Publicado: (2014)

An Exploratory Dose-Escalating Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Atacicept in Patients with Systemic Lupus Erythematosus
por: Pena-Rossi, C, et al.
Publicado: (2009)

Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient‐level placebo (Standard‐of‐Care) data to enable model‐informed drug development
por: Goteti, Kosalaram, et al.
Publicado: (2022)

Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders
por: Kaegi, Celine, et al.
Publicado: (2020)

Immune Response to Enterococcus gallinarum in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies
por: Bagavant, Harini, et al.
Publicado: (2021)

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
por: Isenberg, David, et al.
Publicado: (2015)

CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS
por: Kumar, Gaurav, et al.
Publicado: (2021)

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
por: Rossi, J-F, et al.
Publicado: (2009)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects
por: Willen, Daniela, et al.
Publicado: (2019)

A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells
por: Haselmayer, Philipp, et al.
Publicado: (2017)

Identification of pharmacodynamic biomarker hypotheses through literature analysis with IBM Watson
por: Hatz, Sonja, et al.
Publicado: (2019)

Role of synovial fibroblast subsets across synovial pathotypes in rheumatoid arthritis: a deconvolution analysis
por: Micheroli, Raphael, et al.
Publicado: (2022)

Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial
por: Bandyopadhyay, Somnath, et al.
Publicado: (2017)

Improved cell composition deconvolution method of bulk gene expression profiles to quantify subsets of immune cells
por: Chiu, Yen-Jung, et al.
Publicado: (2019)

Th Subset Balance in Lupus Nephritis
por: Miyake, Katsuhisa, et al.
Publicado: (2011)

Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus
por: Aberle, Teresa, et al.
Publicado: (2017)

Deconvolution of Blood Microarray Data Identifies Cellular Activation Patterns in Systemic Lupus Erythematosus
por: Abbas, Alexander R., et al.
Publicado: (2009)

Deconvolution of cellular subsets in human tissue based on targeted DNA methylation analysis at individual CpG sites
por: Schmidt, Marco, et al.
Publicado: (2020)

Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
por: Gordon, Caroline, et al.
Publicado: (2016)

QuickDeconvolution: fast and scalable deconvolution of linked-read sequencing data
por: Faure, Roland, et al.
Publicado: (2022)

Machine learning applied to whole‐blood RNA‐sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus
por: Figgett, William A, et al.
Publicado: (2019)

Context-aware dimensionality reduction deconvolutes gut microbial community dynamics
por: Martino, Cameron, et al.
Publicado: (2020)

Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus
por: Katsuyama, Takayuki, et al.
Publicado: (2018)

Deconvolution of absorption spectra
por: Blass, William
Publicado: (2012)

Deconvolution: with applications in spectroscopy
por: Jansson, Peter A
Publicado: (1984)

Deconvoluting AMPK dynamics
por: Miyamoto, Takafumi, et al.
Publicado: (2015)

Complement Nomenclature—Deconvoluted
por: Bohlson, Suzanne S., et al.
Publicado: (2019)

The Deconvolution of Human Hematopoiesis
por: Milsom, Michael D.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o32m3m7mmojl38dupkuh7m05ja